US Stock MarketDetailed Quotes

HOOK HOOKIPA Pharma

Watchlist
  • 1.890
  • -0.010-0.53%
Close Feb 14 16:00 ET
18.70MMarket Cap-0.51P/E (TTM)

About HOOKIPA Pharma Company

HOOKIPA Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in developing pharmaceutical products to prevent and cure infectious diseases and cancer. The firm also focuses on immunotherapeutics based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company was founded by Rolf M. Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel D. Pinschewer in 2011 and is headquartered in New York, NY.

Company Profile

SymbolHOOK
Company NameHOOKIPA Pharma
Listing DateApr 18, 2019
Issue Price14.00
Founded2011
CEODr. Malte Peters, M.D.
MarketNASDAQ
Employees179
Fiscal Year Ends12-31
Address350 Fifth Avenue,72nd floor, Suite 7240
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10118
Phone43-1-890-6360
Websitehttp://www.hookipapharma.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Malte Peters, M.D.
  • Director, Chief Executive Officer and President
  • 232.31K
  • Terry Coelho
  • Director, Executive Vice President, Principal Accounting Officer and Chief Financial Officer
  • 85.88K
  • Roman Necina
  • Chief Operations Officer
  • --
  • Mark Winderlich
  • Chief Development Officer
  • --
  • Klaus Orlinger
  • Chief Scientific Officer
  • --
  • Julie O'Neill
  • Non-Executive Chairman of the Board
  • 67.74K
  • Sean A. Cassidy
  • Independent Director
  • --
  • Dr. David Ross Kaufman, M.D.,PhD
  • Independent Director
  • 71.74K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
HENDERA
831152
+30.00%
Hengerda New Materials
300946
+20.01%
Fujian Nebula Electronics.,Ltd
300648
+20.00%
4
Cubic Digital Technology
300344
+19.98%
5
HNAC Technology
300490
+19.95%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
TSLA earnings preview: Grab rewards by guessing the opening price!